Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3Terminated 2

Sponsor Class

NIH 5OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Genitourinary 1CNS 1

Conditions

Neuroblastoma 1Lung Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 956Radiotherapy 847Cisplatin 757Gemcitabine 657Carboplatin 603Docetaxel 598Paclitaxel 585Bevacizumab 580Fluorouracil 504Oxaliplatin 458Rituximab 453Surveys and Questionnaires 449Capecitabine 440Dexamethasone 428Doxorubicin 424Etoposide 411Irinotecan 389Cytarabine 376Filgrastim 369pembrolizumab 330Leucovorin 305Nivolumab 296fludarabine phosphate 294Melphalan 288Magnetic Resonance Spectroscopy 281Peripheral Blood Stem Cell Transplantation 279Blood Specimen Collection 279Methotrexate 276Lenalidomide 276Cetuximab 270

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × OTHER × becatecarin × Clear all
NCT00003737 2013-06-25

Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
30 enrolled
CNS

Neuroblastoma

NCT00005027 2013-04-05

Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00006017 2010-06-10

Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer

Case Comprehensive Cancer Center

Phase 2 Completed
42 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡